Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Monopar Therapeutics Inc.NASDAQ: MNPR

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$5.23M, compared with -$3.22M a year earlier. Trailing-twelve-month operating income was -$18.71M.

Context

  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -3.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.23M+15.1% QoQ
Last fiscal yearDec 2025
-$16.7M-3.4% YoY
LTMMar 2026
-$18.71M-5.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.2%+100.0%+162.2 pp
1 year-3.4%+100.0%+103.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(16.7M) USD
Year-over-year change
-3.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5.9% is the 8th highest of 11, against a peer median of +4.0%.
MNPR Competitors
Operating Income for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$44.15M USD+162.5%—16.6%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$9.56M USD+121.6%—27.2%
MNPRMonopar Therapeutics Inc.LTM Mar 2026-$18.71M USD-5.9%——
IPHAInnate Pharma S.A.FY2025-€53.43M EUR-3.6%—1916.9%
MGNXMacroGenics, Inc.LTM Mar 2026-$63.66M USD+36.0%—40.5%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$75.17M USD-21.6%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$91.17M USD+33.2%——
ADCTADC Therapeutics S.A.LTM Mar 2026-$118.48M USD+5.6%—149.6%
XNCRXencor, Inc.LTM Jun 2026-$216.08M USD-69.5%—205.8%
BCYCBicycle Therapeutics plcLTM Mar 2026-$242.4M USD+2.4%—381.8%
IMNMImmunome, Inc.LTM Sep 2026-$300.69M USD-28.4%——
Peer median (excluding MNPR) —+4.0%—149.6%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.49M7.59M5.6M13.01M9.9B
Selling, General & Admin2.63M2.95M3.23M3.16M6.8B
Operating Expenses9.13M10.54M8.83M16.16M16.7M
Depreciation & Amortization00000
EBITDA(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
EBITDA Margin—————
Operating Income(9.13M)(10.54M)(8.83M)(16.16M)(16.7M)
Operating Margin—————
Interest Income24.02K21.24K429.04K404.02K2.99M
Interest Expense00000
Other Income / Expenses24.02K21.24K429.04K575.3K2.99M
Income Before Tax(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Net Margin—————
EPS (Basic)(0.73)(0.83)(0.58)(1.36)(1.85)
EPS (Diluted)(0.73)(0.83)(0.58)(1.36)(1.85)
Weighted Avg Shares12.47M12.72M14.51M11.44M7.41M
Weighted Avg Shares (Diluted)12.47M12.72M14.51M11.48M7.41M

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.